Popular on eTradeWire
- Pyrrhic Press Publishing Establishes Thought Leadership and Expands Global Influence Through PULSE - 157
- The Common Thread That Unites Us All - 148
- Women's Flag Football Coming to Cal Lutheran - 127
- Volusia Memorial Hosts First Annual Candlelight Service of Remembrance - 114
- AI In Career Development: A Comprehensive Guide - 107
- Shoe Elegance Relaunches as an Online Boutique, Reviving Timeless Style and Sophistication - 105
- Seasonal holiday décor on display at Guadalupe Resale Shop - 103
- UDC Faculty Named Fellows by Academy of International Business - 101
- Rising XR Startup Omnia shows off Virtual Showroom at Tesla Event - 101
- Choosing The Best Bed Bug Extermination Services ✨ - 101
Similar on eTradeWire
- Saving Lives in Schools: The Urgency of CERP Legislation
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
- BHRT Training Academy Announces inaugural BHRT 'Symposium at Sea 2025' for Healthcare Providers
- Start Your Journey To The Right Side Of Happiness With Annamarie Fernyak's New Book Today!
- The Bridge Chiropractic Shares the Top 5 Causes of Knee Pain
- Delray Beach's Grounded Visions Launches Integral Eye Movement Therapy
- 17th Annual Friends & Family Sale by LabNaturals, offering premium CBD, non-toxic skincare, glutathione in Pittsburgh, Pennsylvania
- Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
- Dr. Barrie Matthews of Big Sky Smile Center Speaks at the Full Arch Growth Conference, Inspiring Dentists Nationwide
- Arizona Pharmacy Association Appoints Garet Turner as New CEO
Empowering Asthma Care: Bedfont® Scientific Limited Provides Vital Support for FeNO Testing
eTradeWire News/10788745
Bedfont® outlines key NICE Guideline updates and offers support for healthcare professionals navigating the changes.
MAIDSTONE, U.K. - eTradeWire -- Bedfont® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in designing and manufacturing medical breath analysis devices, welcomes the recent update to the National Institute for Health and Care Excellence (NICE) guidelines on asthma management.
Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing and managing asthma. Nitric oxide is a gas found in exhaled breath that indicates airway inflammation commonly found in eosinophilic asthma.
The previous guidelines for asthma management from NICE recommended FeNO testing alongside other objective tests, such as spirometry and peak flow. A FeNO reading of over 40 parts per billion (ppb) in adults and 35 ppb in children suggested a diagnosis of asthma if carried out with a positive spirometry or peak flow result.
More on eTradeWire News
So, what's new? NICE released the most recent asthma guidelines on Wednesday 27th of November, which recommends a blood test to measure eosinophil levels, or a FeNO test to diagnose asthma in adults. A FeNO test is recommended as the first-line test for an asthma diagnosis in children. Confirmation of a positive asthma diagnosis is a FeNO level exceeding 50 ppb in adults and 35 ppb in children.
It is also proposed that FeNO tests should be offered at regular adult asthma reviews for monitoring, including before and after changing asthma medication. A FeNO test should also be undertaken if a patient presents with poorly controlled asthma.
Jason Smith, CEO at Bedfont® comments "We welcome the updated NICE guidelines, which provide even greater clarity and emphasis on the role of FeNO testing in asthma care. These updates underscore the importance of FeNO testing as an essential tool in improving diagnostic accuracy and tailoring treatment plans to individual patient needs. At Bedfont® we are proud to support healthcare professionals with our innovative NObreath® (https://www.nobreathfeno.com/) FeNO testing device that aligns with the latest clinical guidance, ultimately helping to deliver better outcomes for people with asthma."
More on eTradeWire News
In light of the changes to asthma care and management recommendations, Bedfont® will host various educational resources, such as webinars and articles, to discuss these changes and what they mean for healthcare professionals carrying out FeNO tests.
For a more in-depth look at the guideline updates, read our latest article here (https://www.bedfont.com/new-nice-guidelines-for-asthma-feno-testing-and-the-nobreath-device-in-adult-and-paediatric-care/).
References
Asthma pathway (BTS, NICE, SIGN) [Internet]. National Institute for Health and Care Excellence. 2024. [Cited Wednesday 27th November 2024]. Available from: https://www.nice.org.uk/guidance/ng244
Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing and managing asthma. Nitric oxide is a gas found in exhaled breath that indicates airway inflammation commonly found in eosinophilic asthma.
The previous guidelines for asthma management from NICE recommended FeNO testing alongside other objective tests, such as spirometry and peak flow. A FeNO reading of over 40 parts per billion (ppb) in adults and 35 ppb in children suggested a diagnosis of asthma if carried out with a positive spirometry or peak flow result.
More on eTradeWire News
- OpenID Foundation returns to Gartner IAM Summit to showcase interoperability in action
- Dylan McMahon makes progress on Canada Platforms
- Charity Consultant Vows to Create "Best Ever" Free Digital Training for Charities
- New Book Features Jose Silva's Ultimate Consciousness Expansion Technique
- AG Sues Amazon, But With Wrong D.C. Statute
So, what's new? NICE released the most recent asthma guidelines on Wednesday 27th of November, which recommends a blood test to measure eosinophil levels, or a FeNO test to diagnose asthma in adults. A FeNO test is recommended as the first-line test for an asthma diagnosis in children. Confirmation of a positive asthma diagnosis is a FeNO level exceeding 50 ppb in adults and 35 ppb in children.
It is also proposed that FeNO tests should be offered at regular adult asthma reviews for monitoring, including before and after changing asthma medication. A FeNO test should also be undertaken if a patient presents with poorly controlled asthma.
Jason Smith, CEO at Bedfont® comments "We welcome the updated NICE guidelines, which provide even greater clarity and emphasis on the role of FeNO testing in asthma care. These updates underscore the importance of FeNO testing as an essential tool in improving diagnostic accuracy and tailoring treatment plans to individual patient needs. At Bedfont® we are proud to support healthcare professionals with our innovative NObreath® (https://www.nobreathfeno.com/) FeNO testing device that aligns with the latest clinical guidance, ultimately helping to deliver better outcomes for people with asthma."
More on eTradeWire News
- Solana vs Ethereum: The Blockchain Showdown
- Review Blurbs Declares Andrew Marc Rowe's Hi De Ho, Infecterino!: The Come Up Is 5 Stars Of Infectious Fun
- S.E,Gregg's Radio Interview On "Pursue Your Passion"
- "We Got Your Back: A Dynamite Six Saga" Will Fill Your Teen's Needs and Their Holiday Gift Lists!
- Check out new wave books from trail blazing artist Suave_uk
In light of the changes to asthma care and management recommendations, Bedfont® will host various educational resources, such as webinars and articles, to discuss these changes and what they mean for healthcare professionals carrying out FeNO tests.
For a more in-depth look at the guideline updates, read our latest article here (https://www.bedfont.com/new-nice-guidelines-for-asthma-feno-testing-and-the-nobreath-device-in-adult-and-paediatric-care/).
References
Asthma pathway (BTS, NICE, SIGN) [Internet]. National Institute for Health and Care Excellence. 2024. [Cited Wednesday 27th November 2024]. Available from: https://www.nice.org.uk/guidance/ng244
Source: Bedfont Scientific Ltd.
Filed Under: Health, Healthcare
0 Comments
Latest on eTradeWire News
- OneHouse Global: Here We Grow Again - The Dallas Takeover!
- B2B Success for Regenerative Medicine Providers
- ADELPHI ORCHESTRA's Twenty-first Annual Young Artist Competition
- 100 Films Retreat #7 Screens 15 Productions Representing All Seven of the World's Continents
- Risurance Innovative Solutions Inc. Presents Smart Food Risk Management Tools
- Shoe Elegance Relaunches as an Online Boutique, Reviving Timeless Style and Sophistication
- Food Security Champion for 2024
- Lyna Manufacturing Inc. Gives Back to America This Holiday Season
- CULTURE & COCKTAILS At The Ben Returns on Jan 6 with Award-Winning Comedy Writer ALAN ZWEIBEL
- Winn Claybaugh Interviews Personality Coding Technology Pioneers Cheri Tree and Esther Wildenberg
- Pepper Moon Catering Announces Newest Venue Partnership with Elm & Bain
- Naughty Nevada Band Launches a Bold New Website Design
- Piano to Zanskar Conducts a Musical Journey Across the Himalayas on Documentary Showcase
- Filabot & Massive Dimension Secure Seed Investment to Revolutionize Additive Manufacturing
- Nicole Williams Earns 'Stamp of Approval' as an International Travel Specialist
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
- Daniel Roebuck Brings Christmas Magic to Life as Santa, Saint Nick, and Scrooge
- ATTN: BUSINESS: 'Tis the Season, and here is a GREAT BUSINESS GIFT For Every Business in the World
- Honoring the Pastoral Ministry of The Reverend Doctor Wallace Charles Smith
- BHRT Training Academy Announces inaugural BHRT 'Symposium at Sea 2025' for Healthcare Providers